A study investigating the clinical phenotype of acute graft-versus-host disease (GVHD) in children reveals that one-third of pediatric patients with the disease are not successfully treated with steroids as a primary GVHD therapy.
A study investigating the clinical phenotype of acute graft-versus-host disease (GVHD) in children reveals that one-third of pediatric patients with the disease are not successfully treated with steroids as a primary GVHD therapy.
“Children with acute GHVD are usually treated with therapies studied predominantly in adults with assumptions as to the expected effectiveness in younger patients. As children have unique underlying diseases, comorbidities, and pharmacokinetics, the characteristics of acute GVHD in children and response to therapy may differ from adults and warrants specific investigation,” the authors said.
The study, published in Bone Marrow Transplant, investigated 370 pediatric University of Minnesota allogeneic hematopoietic cell transplantation (HCT) patients who developed grade I-IV acute GVHD between January 1990 and December 2016. The patients evaluated were treated systemically with prednisone 60 mg/m2/day day followed by an 8-week taper as initial therapy.
After day 28, the overall response occurred in 65% of patients. The researchers noted that initial GVHD grade did not predict day 28 response, but the Minnesota GVHD Risk Score predicted response with 68% standard risk patients achieving complete or partial response at day 28.
“This is the largest pediatric series examining the clinical phenotype of acute GVHD at diagnosis and response to uniform upfront steroid therapy. The strength of these data include weekly GVHD organ staging, structured protocol driven eligibility, and uniform upfront GVHD therapy, facilitating identification of patient and transplant factors associated with outcomes,” the authors said.
The researchers concluded that innovative GVHD trials need to be conducted to evaluate less toxic therapies for standard risk patients and novel approaches for patients with high risk GVHD.
“If established drug treatment regimens from studies in adults are to be repurposed for novel pediatric GVHD trials, careful dose escalation studies may need to be performed in children to establish the optimal dose and schedule of new GVHD agents,” they said. “As the clinical phenotype of acute GVHD in children is different than adults, pediatric specific GVHD trials may be warranted.”
Reference
Macmillan ML, Holtan SG, Rashidi A, et al. Pediatric acute GVHD: clinical phenotype and response to upfront steroids [published online January 2020]. Bone Marrow Transplant. doi:10.1038/s41409-019-0651-9.
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
January 23rd 2024Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Interventions Needed to Increase DMT Uptake in Sickle Cell Disease
December 26th 2023A recent study found that uptake of disease-modifying therapies (DMTs) has been low among patients with sickle cell disease, suggesting that more interventions that consider individual patient characteristics are needed to improve adoption.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More